Pharming Group Provides Update On Outstanding Shares

LEIDEN, NETHERLANDS--(Marketwire - May 17, 2010) -

Biotech company Pharming Group NV ("Pharming") (NYSE Euronext: PHARM) today provided an update on its outstanding number of shares.

As result of various conversion notices, totalling EUR2.0 million, from the January 2010 EUR7.5 million Private Bonds, Pharming issued a total amount 6,256,028 ordinary shares in return for these conversions. These conversions have reduced the nominal value of the Bonds bonds issued in January 2010 to EUR4.8 million. As a result, Pharming's total number of outstanding ordinary shares is currently 162,921,104.

About Pharming Group NV

Pharming Group NV is developing innovative products for the treatment of genetic disorders, ageing diseases, specialty products for surgical indications, and nutritional products. Pharming's lead product Rhucin® for acute attacks of Hereditary Angioedema has passed clinical development stage and the Market Authorization Application is under review with the European Medicines Agency. Prodarsan® is in early stage clinical development for Cockayne Syndrome and lactoferrin for use in food products. The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, technology and processes for the purification and formulation of these products, as well as technology in the field of DNA repair (via DNage). Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.

Contact:

Ms. Marjolein van Helmond, Pharming Group NV, T: +31 (0)71 52 47 431
or +31 (0)6109 299 54

[HUG#1416168]

Press Release (PDF): http://hugin.info/132866/R/1416168/366822.pdf